<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701324</url>
  </required_header>
  <id_info>
    <org_study_id>1247.1</org_study_id>
    <secondary_id>2007-000191-17</secondary_id>
    <nct_id>NCT00701324</nct_id>
  </id_info>
  <brief_title>BI 811283 in Various Solid Tumours</brief_title>
  <official_title>An Open Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 811283 Administered Intravenously Over 24 h Continuous Infusion in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The main objective of this trial is to provide safety data in terms of drug-related adverse
      events (AE) for the recommendation of the dose for further trials in the development of BI
      811283.

      Secondary objectives are the collection of antitumour efficacy data and the determination of
      the pharmacokinetic profile of BI 811283.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>3-4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile: incidence and intensity of AEs graded according to the common terminology criteria for AEs, incidence of DLT</measure>
    <time_frame>throughout the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS), Objective response, Response duration, Pharmacodynamic analysis, Basic pharmacokinetics</measure>
    <time_frame>throughout the study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 811283, 24h infusion d1 and d15 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 811283, 24h infusion d1 every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 811283</intervention_name>
    <description>dose escalation BI 811283, Arm B (3 weeks)</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 811283</intervention_name>
    <description>dose escalation BI 811283, Arm A (day 1)</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 811283</intervention_name>
    <description>dose escalation BI 811283, Arm A (day 15)</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patients with confirmed diagnosis of advanced, non-resectable and/or metastatic solid
        tumours, who have failed conventional treatment or for whom no therapy of proven efficacy
        exists or who are not amenable to established treatment options Secure central venous
        access Evaluable tumour deposits Recovery from reversible toxicities of prior anti-cancer
        therapies Age &gt;= 18 years Life expectancy &gt;= 6 months Written informed consent in
        accordance with International Conference on Harmonisation (ICH) guideline for Good Clinical
        Practice (GCP) and local legislation Eastern Cooperative Oncology Group performance score
        &lt;= 2

        Exclusion criteria:

        Serious illness, concomitant non-oncological disease (e.g. active infectious disease), or
        ongoing toxicity of prior therapies considered by the investigator to potentially
        compromise patients' safety in this trial Pregnancy or breastfeeding Known brain metastases
        Second malignancy requiring therapy Left ventricular ejection fraction (LVEF) &lt; 50% in
        echocardiography or clinical congestive heart failure New York Heart Association grade III
        - IV Myocardial infarction within the last 6 months prior to inclusion or symptomatic
        coronary artery disease Absolute neutrophil count less than 1500 / mm3 Platelet count less
        than 100 000 / mm3 Bilirubin greater than 1.5 mg / dl (&gt; 26 mcmol / L, SI unit equivalent)
        Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5
        times the upper limit of normal (if related to liver metastases greater than five times the
        upper limit of normal) Serum creatinine greater than 1.5 mg / dl (&gt; 132 mcmol / L, SI unit
        equivalent) Women and men who are sexually active and unwilling to use a medically
        acceptable method of contraception Treatment with other investigational drugs or in another
        clinical trial within the past two weeks before start of therapy or concomitantly with this
        trial Chemo-, hormone, radio- or immunotherapy within the past two weeks before start of
        therapy or concomitantly with this trial Patients unable to comply with the protocol Active
        alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1247.1.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1247.1.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg/Breisgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>July 21, 2014</last_update_submitted>
  <last_update_submitted_qc>July 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

